• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity

tetano

Editor, Senior Moderator
Sci Adv


. 2021 Aug 18;7(34):eabf8609.
doi: 10.1126/sciadv.abf8609. Print 2021 Aug.
Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity


Zintis Inde[SUP] 1 2 [/SUP], Ben A Croker[SUP] 3 [/SUP], Clarence Yapp[SUP] 2 4 [/SUP], Gaurav N Joshi[SUP] 1 2 5 [/SUP], Johan Spetz[SUP] 1 2 [/SUP], Cameron Fraser[SUP] 1 2 [/SUP], Xingping Qin[SUP] 1 2 [/SUP], Le Xu[SUP] 6 [/SUP], Brian Deskin[SUP] 1 [/SUP], Elisa Ghelfi[SUP] 1 [/SUP], Gabrielle Webb[SUP] 1 [/SUP], Aaron F Carlin[SUP] 6 [/SUP], Yanfang Peipei Zhu[SUP] 3 [/SUP], Sandra L Leibel[SUP] 3 7 8 [/SUP], Aaron F Garretson[SUP] 6 [/SUP], Alex E Clark[SUP] 6 [/SUP], Jason M Duran[SUP] 6 [/SUP], Victor Pretorius[SUP] 9 [/SUP], Laura E Crotty-Alexander[SUP] 6 [/SUP], Chendi Li[SUP] 10 [/SUP], Jamie Casey Lee[SUP] 3 [/SUP], Chhinder Sodhi[SUP] 11 [/SUP], David J Hackam[SUP] 11 [/SUP], Xin Sun[SUP] 3 [/SUP], Aaron N Hata[SUP] 10 12 [/SUP], Lester Kobzik[SUP] 1 [/SUP], Jeffrey Miller[SUP] 1 [/SUP], Jin-Ah Park[SUP] 1 [/SUP], Douglas Brownfield[SUP] 1 [/SUP], Hongpeng Jia[SUP] 11 [/SUP], Kristopher A Sarosiek[SUP] 13 2 [/SUP]



Affiliations

Abstract

Novel coronavirus disease 2019 (COVID-19) severity is highly variable, with pediatric patients typically experiencing less severe infection than adults and especially the elderly. The basis for this difference is unclear. We find that mRNA and protein expression of angiotensin-converting enzyme 2 (ACE2), the cell entry receptor for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19, increases with advancing age in distal lung epithelial cells. However, in humans, ACE2 expression exhibits high levels of intra- and interindividual heterogeneity. Further, cells infected with SARS-CoV-2 experience endoplasmic reticulum stress, triggering an unfolded protein response and caspase-mediated apoptosis, a natural host defense system that halts virion production. Apoptosis of infected cells can be selectively induced by treatment with apoptosis-modulating BH3 mimetic drugs. Notably, epithelial cells within young lungs and airways are more primed to undergo apoptosis than those in adults, which may naturally hinder virion production and support milder COVID-19 severity.
 
Back
Top Bottom